An interventional study of Metformin Hydrochloride 500 MG in Drug Use, sponsored by PT. Pyridam Farma Tbk. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 52 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-03.
Sponsored by PT. Pyridam Farma Tbk · Not applicable, Interventional, and Basic science
The objective of this present study was to investigate whether Glufor® 500 (metformin hydrochloride 500 mg) film-coated tablets manufactured by PT. Pyridam Farma Tbk is bioequivalent to its reference product, Glucophage® 500 mg film-coated tablets manufactured by PT. Merck Tbk, Indonesia under licensed Merck Sante SAS, France.
Twenty-four subjects were given a single dose of 500 mg Metformin film-coated tablet of either formulation (test or reference) with 240 mL of a 20% glucose solution in water.
This is the only study on the registry with PT. Pyridam Farma Tbk as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The inclusion criterias were healthy male or female subjects who/with:
Exclusion criterias
The subjects' exclusion criterias for the study were:
Drug: Metformin Hydrochloride 500 MG
Drug: Metformin Hydrochloride 500 MG
Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Geometric Mean Ratio
The ratio between maximum concentration of test drug and reference drug after drug administration
Time frame: 0-24 hours post dose
Geometric Mean Ratio
The ratio between area under curve from 0 to 24 hours of test drug and reference drug
Time frame: 0-24 hours post dose
Pharmacokinetics Parameter
Maximum plasma concentration (Cmax)
Time frame: 0-24 hours post dose
Pharmacokinetics Parameter
Area Under Curve from 0 to 24 hours (AUCt)
Time frame: 0-24 hours post dose
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.